Frost & Sullivan Report Recognizes FireEye as Leading
Frost & Sullivan Report Recognizes FireEye as Leading Provider of "Must Have" Network Security Technology for Advanced Attacks
Combination of Features and 62 Percent Market Share Establish FireEye as Clear Segment Leader
MILPITAS, CA -- (Marketwired) -- 08/05/15 -- FireEye, Inc. (NASDAQ: FEYE), the leader in stopping today's advanced cyber attacks, today announced that a new report from Frost & Sullivan recognizes FireEye as the leading vendor in the network security sandbox market. A half billion market in 2014, the network security sandbox segment is expected to grow to $3.5 billion by 2019, with an average compound annual growth rate (CAGR) of 45.6 percent from 2014-19.
The report, Network Security Sandbox Market Analysis: APTs Create a "Must Have" Security Technology, examines the rapidly growing market for network security sandbox technologies in response to the rise of advanced attack. Network security sandbox technologies, which execute and analyze suspicious software in a controlled environment, use sophisticated algorithms to detect and validate previously unseen attacks missed by signature-based detection technologies.
"The network security sandbox segment is dominated by FireEye, which commands almost two-thirds of 2014 market revenue," said Frank Dickson, research director with Frost & Sullivan. "A combination of network security sandbox features and large market share puts FireEye in the position of clear leadership. FireEye continues to capitalize on its first-mover advantage."
"Advanced attackers are transforming the threat landscape," said Manish Gupta, senior vice of products at FireEye. "This Frost & Sullivan report recognizes that advanced threats are the 'new normal,' and organizations of all sizes and in all industries must realign their security budgets to protect their intellectual property and data. FireEye network, endpoint and cloud-based security products, powered by our MVX virtual machine detection engine, help customers build attack-resilient networks. When combined with our FireEye-as-a-Service and advanced threat intelligence offerings, FireEye products reduce the time from security alert to remediation and mitigate the risks of an attack."
A complimentary excerpt of the new Frost & Sullivan report is available at: https://www.fireeye.com/content/dam/fireeye-w...alysis.pdf
About FireEye, Inc.
FireEye has invented a purpose-built, virtual machine-based security platform that provides real-time threat protection to enterprises and governments worldwide against the next generation of cyber attacks. These highly sophisticated cyber attacks easily circumvent traditional signature-based defenses, such as next-generation firewalls, IPS, anti-virus, and gateways. The FireEye Threat Prevention Platform provides real-time, dynamic threat protection without the use of signatures to protect an organization across the primary threat vectors and across the different stages of an attack life cycle. The core of the FireEye platform is a virtual execution engine, complemented by dynamic threat intelligence, to identify and block cyber attacks in real time. FireEye has over 3,700 customers across 67 countries, including 675 of the Forbes Global 2000.
© 2015 FireEye, Inc. All rights reserved. FireEye, Email Threat Prevention Platform, EX, Advanced Threat Intelligence and ATI are registered trademarks or trademarks of FireEye, Inc. in the United States and other countries. All other brands, products, or service names are or may be trademarks or service marks of their respective owners.
Source: FireEye
Mandiant, Inc. (MNDT) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....
Continue Reading
Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...
Continue Reading
AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...
Continue Reading
A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...
Continue Reading
History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...
Continue Reading
You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...
Continue Reading
Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...
Continue Reading
Top 5 Most Recently Viewed Articles
America's Car-Mart Secures Funding for Future Growth America's Car-Mart, Inc. (NASDAQ: CRMT), a leading automotive retailer, has taken a strategic step by closing a significant five-year, $300 million term loan. This loan, managed by the seasoned professionals at Silver Point Capital, L.P., aims to enhance the company’s capital structure and support its long-term growth...
Continue Reading
IASO Bio’s Major Step Forward with New Drug Application IASO Biotherapeutics, a pioneering biopharmaceutical company dedicated to the advancement of innovative cell therapies and biologics, has reached a significant milestone. The Singapore Health Sciences Authority (HSA) has officially accepted the New Drug Application (NDA) for Equecabtagene Autoleucel, known as...
Continue Reading
Empowering Students to Make a Difference The student-led organization is providing career opportunities while connecting with the community. National Heritage Academies® (NHA) is thrilled to celebrate its collaboration with United Way through the Student United Way program. This initiative equips high school students with essential tools and opportunities to enact...
Continue Reading
Exploring the Growth of Augmented Reality and Virtual Reality Market The global market for Augmented Reality (AR) and Virtual Reality (VR) is on the rise, with expectations of substantial growth over the next few years. Analysts estimate that this sector will expand by approximately USD 442.99 billion between 2024 and 2028. The compound annual growth rate (CAGR) for this...
Continue Reading
ImmVira Leads the Way with Groundbreaking Exosome Technology In a remarkable advancement for the cosmetic industry, ImmVira Group has announced its innovative product, MVR-EX103, an engineered exosome specifically developed for treating superficial skin depressions. This development marks a pivotal moment, as it has successfully acquired the International Nomenclature...
Continue Reading